Diabetic Perspectives

The Application of Umbilical Cord Blood Cells in the Treatment of Diabetes Mellitus

Tomas Koblas¹, S. Mitchell Harman², Frantisek Saudek¹

Keywords: diabetes, umbilical cord blood, differentiation, β-cells

Abstract

In recent years, human umbilical cord blood (HUCB) has emerged as an attractive tool for cell-based therapy. Although at present the clinical application of HUCB is limited to the fields of hematology and oncology, a rising number of studies show potential for further application in the treatment of non-hematopoietic diseases. HUCB, with its real abundance, simple collection procedure and no serious ethical dilemmas, represents a valuable alternative to the use of other stem cell sources. The aim of this article is to review the literature on HUCB and to assess its eventual usability in the treatment of diabetes mellitus. This review presents some recent reports concerning pancreatic endocrine stem cells and their identification, HUCB stem cells and their advantages and, finally, the potential for converting HUCB-derived stem cells into insulin-producing β-cells.

Fulltext: HTML , PDF (300KB)

This article has been cited by other articles:

	Insulin-producing cells derived from stem/progenitor cells: therapeutic implications for diabetes mellitus Hori Y Med Mol Morphol 2009. 42(4):195-200
	In vitro culture and differentiation of osteoblasts from human umbilical cord blood Toai TC, Thao HD, Thao NP, Gargiulo C, Ngoc PK, Van PH, Strong DM Cell Tissue Bank 2009. Jun 30, epub ahead of print
	Potential myogenic stem cell populations: sources, plasticity and application for cardiac repair Schabort EJ, Myburgh KH, Wiehe JM, Torzewski J, Niesler CU Stem Cells Dev 2009. 18(6):813-830
	The current status of islet transplantation and its perspectives Kobayashi N Rev Diabet Stud 2008. 5(3):136-143
	Stem cells and the mammary microenvironment Booth BW, Boulanger CA, Smith GH Breast Dis 2008. 29:57-67
	Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer Mimeault M, Batra SK Gut 2008. 57(10):1456-1468
	Mesenchymal Stem Cells - Sources and Clinical Applications Klingemann H, Matzilevich D, Marchand J Transfus Med Hemother 2008. 35(4):2
	Stem Cell Strategies for Pancreatic beta-cell Wu X, Woo M Endocrinol Rounds 2008. 8(4):1-6
	Characterization of adipose tissue-derived cells isolated with the Celution system Lin K, Matsubara Y, Masuda Y, Togashi K, Ohno T, Tamura T, Toyoshima Y, Sugimachi K, Toyoda M, Marc H, Douglas A Cytotherapy 2008. 10(4):417-426
	Mesenchymal stem cells: Biology and clinical potential in Type 1 Diabetes Therapy Liu M, Han ZC J Cell Mol Med 2008. 12(4):1155-1168
	Cellular therapies for type 1 diabetes Lee DD, Grossman E, Chong AS Horm Metab Res 2008. 40(2):147-154
	Stem Cell Treatment for Complicated Diabetes Bahk JY, Han H, Lee YS Int J Stem Cells 2008. 1(1):91-95
	Mesenchymal Stromal Cells from Umbilical Cord Blood Bieback K, Kluter H Curr Stem Cell Res Ther 2007. 2(4):310-323
	Transplantation in the treatment of diabetes Saudek F Vnitr Lek 2007. 53(7-8):859-864